Aquestive saw revenue growth driven by its manufacturing business, though net losses widened significantly due to one-time legal settlement costs and increased pre-commercial spending for Anaphylm. The company is focused on resubmitting its Anaphylm NDA in Q3 2026 following a Type A meeting with the FDA.

Aquestive Therapeutics had a strong third quarter in 2025, with total revenues of $12.8 million and a net loss of $15.4 million. The company is actively preparing for the potential U.S. launch of Anaphylm in Q1 2026, while also advancing regulatory activities in Canada and the EU. The balance sheet was strengthened to support future commercialization efforts.

Aquestive Therapeutics reported a decrease in total revenue to $10.0 million in Q2 2025 from $20.1 million in Q2 2024, primarily due to a one-time deferred revenue recognition in the prior year. Excluding this impact, revenue increased by 3%. The company's net loss widened to $13.5 million, or $0.14 per share, compared to a net loss of $2.7 million in the same period last year. Despite the financial decline, Aquestive made significant strides in its pipeline, with the FDA accepting the NDA for Anaphylm and setting a PDUFA date for January 31, 2026, alongside accelerating global expansion plans for the product.

Aquestive Therapeutics generated $8.7 million in revenue for Q1 2025, down 28% year-over-year, due to declines in manufacturing and license revenues. The company intensified its commercial readiness efforts for Anaphylm and reduced non-core development activities.

Aquestive Therapeutics posted a revenue decline of 10% in Q4 2024, with total revenue at $11.9 million. The company reported a net loss of $17.1 million due to increased R&D and SG&A expenses. Non-GAAP adjusted EBITDA loss widened to $11.0 million. The company continued its regulatory progress on Anaphylm and Libervant, while manufacturing and supply revenues also declined.

Aquestive Therapeutics reported a 4% increase in total revenues to $13.5 million for the third quarter of 2024, driven by increases in license and royalty revenue, offset by decreases in manufacture and supply revenue. The company is advancing its key product candidates, Anaphylm and AQST-108, with pre-NDA and pre-IND meetings scheduled for the fourth quarter of 2024, respectively. Aquestive finished the quarter with approximately $78 million in cash and reaffirms its cash runway into 2026.

Aquestive Therapeutics reported a 52% increase in total revenues to $20.1 million for the second quarter 2024, driven by increases in license and royalty revenue. The company's net loss decreased to $2.7 million, or $0.03 per share, compared to a net loss of $5.8 million, or $0.10 per share, for the second quarter 2023. Cash and cash equivalents were approximately $90 million as of June 30, 2024, and the company reaffirms cash runway into 2026.

Aquestive Therapeutics reported an 8% increase in total revenues to $12.1 million for Q1 2024, driven primarily by higher revenue from out-licensed products. The company highlighted the successful completion of the Anaphylm Phase 3 study and FDA approval for Libervant in patients aged 2-5, extending their cash runway into 2026.

Aquestive Therapeutics reported a strong finish to 2023 with double-digit base revenue growth and an improved balance sheet. The company is focused on progressing Anaphylm to a US filing, expanding its revenue base, and advancing its pipeline assets.

Aquestive Therapeutics reported a 42% increase in revenue, excluding the impact of prior year proprietary sales of Sympazan, driven by higher revenue from out-licensed products. The company's net loss decreased, and non-GAAP adjusted EBITDA loss improved compared to the prior year.

Aquestive Therapeutics reported second quarter 2023 financial results with a total revenue of $13.2 million and a net loss of $5.8 million, marking a significant decrease compared to the previous year's net loss of $16.3 million. Excluding the impact of prior year proprietary sales of Sympazan, total revenues increased from $10.7 million in the second quarter 2022 to $13.2 million in the second quarter 2023, driven by higher revenue from out-licensed products. The company is advancing its product pipeline, including Anaphylm and Libervant, and has updated its full-year 2023 financial guidance.

Aquestive Therapeutics reported a revenue of $11.134 million and a net income of $8.068 million for Q1 2023. The company saw an increase in license and royalty revenue, co-development and research fees, and manufacture and supply revenue. They are advancing the development of Anaphylm and reaffirming their commitment to pursue early market access for Libervant.

Aquestive Therapeutics reported a decrease in total revenues for Q4 2022, with a net loss of $12.4 million, but showed progress in financial turnaround actions including debt reduction and securing non-dilutive capital. The company is focused on advancing AQST-109, working with the FDA for Libervant, expanding manufacturing capabilities, and strengthening its balance sheet.